Final Results

AI SummaryClose X

Solvonis Therapeutics plc reported its audited results for the year ended 31 December 2025, detailing a transformational year that included the acquisition of Awakn Life Sciences and a strategic refinement to focus on its SVN-001 Phase 3 program for severe Alcohol Use Disorder. The company ended the year with £1.720 million in cash and cash equivalents, which is expected to fund operations through the end of 2026. The Board has concluded that advancing SVN-001 through Phase 3 completion, rather than an earlier licensing deal, offers greater potential for shareholder value, especially given recent positive developments in the US biopharmaceutical market for psychedelic drugs and the acquisition of Transcend Therapeutics for up to $1.225 billion.

Disclaimer*

UK 100

Latest directors dealings